Onyx Files Carfilzomib NDA, Shoots for Accelerated Approval

Onyx Pharmaceuticals Inc.'s submission of a new drug application (NDA) for its multiple myeloma drug, carfilzomib, is an audacious move that has investors biting their nails. The strength of the submission rests on study 003-A1, an open-label, single-arm Phase IIb trial in 266 heavily pretreated patients with relapsed and refractory multiple myeloma.